Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
|ClinicalTrials.gov Identifier: NCT00831480|
Recruitment Status : Terminated (Difficulty in accrual and by the order of the cancer center.)
First Posted : January 29, 2009
Results First Posted : March 21, 2016
Last Update Posted : March 21, 2016
The purpose of this multicenter, pilot, open-label, Phase II clinical trial is to discover if Everolimus(RAD001) is safe and effective in people who have advanced kidney cancer (renal cell carcinoma - RCC).
Since 2002, Everolimus has been studied in more than 2500 patients with various types of cancer as a single agent (a drug that is used alone to treat the cancer) or in combination with a number of well known anticancer therapies. Various studies, in animals such as in mice with cancer and in humans with cancer have shown that Everolimus can slow the growth of cancer.
Everolimus will be taken in pill form by mouth daily for 3-5 weeks followed by surgery to remove the effected kidney. After 2-4 weeks following the surgery, Everolimus will be resumed at the same dose.
|Condition or disease||Intervention/treatment||Phase|
|Kidney Cancer||Drug: everolimus||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Neoadjuvant Everolimus (RAD001)for Advanced RCC Before Cytoreductive Nephrectomy, With Correlative Tumor Studies (Protocol #: 06-08-20-01)|
|Study Start Date :||April 2011|
|Primary Completion Date :||November 2013|
|Study Completion Date :||December 2014|
All subjects will take everolimus
everolimus 10 mg PO once daily for 3-5 weeks followed by removal of the kidney. Everolimus will begin again between 2 to 4 weeks after surgery.
- Disease Progression Diagnosed by Biopsy [ Time Frame: up to one year ]Clinical progression validated by biopsy of metastatic site. Progression-free survival (PFS) will be measured from the post-op treatment start date to either the date the patient is first recorded as having disease progression, or the date of death if the patient dies due to any causes before progression. If a patient is lost to follow-up or removed for toxicities, the patient will be censored as of the last date of contact. Patients who start a new treatment before they progress will be censored as of the date of start of the new treatment. If a patient has not progressed or died, PFS is censored at the date of last follow-up. Patients removed from therapy with everolimus due to toxicities will not be included in the PFS estimation.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00831480
|United States, Texas|
|UT Southwestern Medical Center|
|Dallas, Texas, United States, 75390|
|Baylor College of Medicine|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Gilad E. Amiel, MD||Baylor College of Medicine|